Newswise — After a decade of crushing setbacks in clinical trials, Alzheimer’s disease researchers all around the world are building integrated systems to run cheaper, faster, and hopefully more successful studies. Large registries, partnerships with health-care providers, and other outreach efforts are supposed to reach hundreds of thousands of people, and entice them to join cohorts where those at high risk get phenotyped and invited to join therapeutic trials. Europe, North America, Australia, and Japan are all on this path. Will it work? Gabrielle Strobel’s three-part series examines the outlook for joint efforts by the Global Alzheimer’s Platform and the European Prevention of Alzheimer’s Dementia. She covers new ways in which GAP and EPAD are reaching out to people and how trial centers are positioning themselves as standing networks, with standardized paperwork, clinical rater systems, and a central IRB, for trials anticipated to start late next year.

About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.

Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.

Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.

Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies.Alzforum does not endorse any specific product or scientific approach.